Neuropsychiatric Adverse Events in Brodalumab Psoriasis Studies

Mark Lebwohl; Kim A Papp; Jashin J Wu; Andrew Blauvelt; Alan Menter; Shipra Rastogi; Radhakrishnan Pillai; Robert Israel

doi:10.25251/skin.1.supp.24

Mark Lebwohl
Kim A Papp
Jashin J Wu
Andrew Blauvelt
Alan Menter
Shipra Rastogi
Radhakrishnan Pillai
Robert Israel

Keywords

neuropsychiatric, adverse events, psoriasis, brodalumab

Abstract

Abstract Not Available

Poster PDF

Published

Oct 27, 2017

DOI https://doi.org/10.25251/skin.1.supp.24

How to Cite

Lebwohl, M., Papp, K. A., Wu, J. J., Blauvelt, A., Menter, A., Rastogi, S., Pillai, R., & Israel, R. (2017). Neuropsychiatric Adverse Events in Brodalumab Psoriasis Studies. SKIN The Journal of Cutaneous Medicine, 1(3.1), s25. https://doi.org/10.25251/skin.1.supp.24

Issue

Vol. 1 (2017): Supplemental Issue: Scientific Posters Presented at 2017 Fall Clinical Dermatology Conference®-Las Vegas

Section

Poster Presentations from FC23 Dermatology Conference®: Psoriasis

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by the following user license:

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Most read articles by the same author(s)

Umair Khan, Nahla Shihab, Robert G Phelps, Mark Lebwohl, Successful Treatment of Pityriasis Rubra Pilaris with Brodalumab , SKIN The Journal of Cutaneous Medicine: Vol. 4 No. 2 (2020)
Alan Menter, Jeff Sobell, Jonathan I Silverberg, Mark Lebwohl, Shipra Rastogi, Radhakrishnan Pillai, Robert J Israel, Long-Term Efficacy of Brodalumab for the Treatment of Moderate-to-Severe Psoriasis: Data from a Pivotal Phase 3 Clinical Trial , SKIN The Journal of Cutaneous Medicine: Vol. 2 (2018): Supplemental Issue: Scientific Posters Presented at 2018 Winter Clinical Dermatology Conference®-Hawaii
Kim A Papp, Joseph F Merola, Alice B Gottlieb, Christopher EM Griffiths, Kristina K Harris, Nancy Cross, Luke Peterson, Christopher Cioffi, Andrew Blauvelt, Bimekizumab provides rapid and sustained improvements in quality of life that correlate with clinical outcomes in patients with moderate to severe plaque psoriasis: 60 week results from a randomized , double blinded , Phase 2b extension study , SKIN The Journal of Cutaneous Medicine: Vol. 3 (2019): Supplemental Issue: Scientific Posters Presented at 2019 Fall Clinical Dermatology Conference®-Las Vegas
Richard G Langley, Jeffrey Crowley, Melinda Gooderham, Kim A Papp, Neil J Korman, Lynda Spelman, Atsuyuki Igarashi, Mamitaro Ohtsuki, Aditya K Gupta, Paul Yamauchi, Jeffrey Parno, Alan M Mendelsohn, Stephen J Rozzo, Kimberly Eads, Efficacy and Safety of Long-Term Tildrakizumab for Plaque Psoriasis: 4-Year Results from Resurface 1 and Resurface 2 , SKIN The Journal of Cutaneous Medicine: Vol. 4 No. 5 (2020): September Issue & Poster Presentations (FCPANP20® Dermatology Conference)
Leon Kircik, Todd Schlesinger, April Armstrong, Brian Berman, Neal Bhatia, James Del Rosso, Mark Lebwohl, Vishal A. Patel, Darrell Rigel, Siva Narayanan, Volker Koscielny, Ismail Kasujee, Impact of Actinic Keratosis (AK), as measured by patient-reported AK symptoms, and impact on emotions and functioning (using Skindex-16) among patients with AK administered tirbanibulin in real-world community practices across the U.S. (PROAK Study) , SKIN The Journal of Cutaneous Medicine: Vol. 7 No. 2 (2023): March Issue & Poster Presentations from WCH23 Dermatology Conference®
Andrew Blauvelt, Andrew Pink, Margitta Worm, Richard Langley, Antonio Costanzo, Le Gjerum, Emilie Jorgensen, Joshua Corriveau, Emma Guttman-Yassky, COVID-19 in tralokinumab-treated patients with moderate-to- severe atopic dermatitis: case series from the ECZTEND long- term extension trial , SKIN The Journal of Cutaneous Medicine: Vol. 5 No. 6 (2021): November Issue & Poster Presentations (FC21 Dermatology Conference®)
Linda Stein Gold, MD, Leon H. Kircik, MD, Emil A Tanghetti, MD, Hilary Baldwin, MD, Zoe D. Draelos, MD, Michael Gold, MD, Edward Lain, MD, MBA, David M Pariser, MD, Neil Sadick, MD, Radhakrishnan Pillai, PhD, Varsha Bhatt, PhD, Efficacy and Safety of a Fixed-Dose Clindamycin Phosphate 1.2%, Benzoyl Peroxide 3.1%, and Adapalene 0.15% Gel for Moderate-to-Severe Acne: Randomized Phase 2 and Phase 3 Studies of the First Triple-Combination Drug , SKIN The Journal of Cutaneous Medicine: Vol. 7 No. 2 (2023): March Issue & Poster Presentations from WCH23 Dermatology Conference®
Mark Lebwohl, Michael Bukhalo, Linda Stein Gold, Michelle Pelle, Bradley Glick, Mar Llamas-Velasco, Samuel Sanchez-Rivera, Tianyu Zhan, Leonidas Drogaris, Kevin Douglas, Greg St. John, Ramon Espaillat, Robert Bissonnette, A Phase 3b Study Evaluating Safety and Efficacy of Risankizumab in Adult Patients with Moderate-to-Severe Plaque Psoriasis with Palmoplantar (Non-Pustular) Involvement , SKIN The Journal of Cutaneous Medicine: Vol. 7 No. 6 (2023): November 2023 Issue
Kristian Reich, Andrew Blauvelt, Diamant Thaci, Craig Leonardi, Yves Poulin, Daniel Burge, Luke Peterson, Catherine Arendt, Alice B Gottlieb, Maintenance of Response with Certolizumab Pegol for the Treatment of Chronic Plaque Psoriasis: 48-Week Results from Two Ongoing Phase 3, Multicenter, Randomized, Placebo-Controlled Studies (CIMPASI-1 and CIMPASI-2) , SKIN The Journal of Cutaneous Medicine: Vol. 1 (2017): Supplemental Issue: Scientific Posters Presented at 2017 Fall Clinical Dermatology Conference®-Las Vegas
Neal Bhatia, April W Armstrong, Todd Schlesinger, Leon Kircik, Brian Berman, Mark Lebwohl, Darrell Rigel, Vishal A Patel, James Del Rosso, Ayman Grada, Siva Narayanan, Ismail Kasujee, An Expert Panel Questionnaire for Assessing Patient-Reported and Clinician-Reported Outcomes in Actinic Keratosis , SKIN The Journal of Cutaneous Medicine: Vol. 6 No. 6 (2022): November Issue & Poster Presentations from FC22 Dermatology Conference®

<< < 5 6 7 8 9 10 11 12 13 14 > >>

Main Article Content

Keywords

Abstract

Article Sidebar

Article Details

Most read articles by the same author(s)